| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 154 | 2025 | 2067 | 17.750 |
Why?
|
| Anti-HIV Agents | 30 | 2025 | 345 | 4.680 |
Why?
|
| Patient Compliance | 24 | 2018 | 479 | 4.180 |
Why?
|
| Medication Adherence | 19 | 2020 | 338 | 3.920 |
Why?
|
| Patient Acceptance of Health Care | 22 | 2018 | 471 | 3.600 |
Why?
|
| Antiretroviral Therapy, Highly Active | 28 | 2015 | 269 | 2.980 |
Why?
|
| Viral Load | 23 | 2020 | 412 | 2.920 |
Why?
|
| Mass Screening | 19 | 2022 | 833 | 2.710 |
Why?
|
| Adrenal Cortex Neoplasms | 15 | 2025 | 34 | 2.680 |
Why?
|
| Anti-Retroviral Agents | 12 | 2025 | 150 | 2.650 |
Why?
|
| Health Services Accessibility | 15 | 2019 | 648 | 2.630 |
Why?
|
| Continuity of Patient Care | 9 | 2018 | 154 | 2.530 |
Why?
|
| AIDS Serodiagnosis | 9 | 2019 | 57 | 2.380 |
Why?
|
| Patient-Centered Care | 8 | 2020 | 236 | 2.320 |
Why?
|
| Physician-Patient Relations | 9 | 2018 | 446 | 2.130 |
Why?
|
| Trust | 7 | 2017 | 80 | 2.020 |
Why?
|
| Adult | 125 | 2025 | 31946 | 1.920 |
Why?
|
| Delivery of Health Care | 13 | 2020 | 679 | 1.890 |
Why?
|
| Middle Aged | 110 | 2025 | 29394 | 1.710 |
Why?
|
| HIV | 9 | 2024 | 195 | 1.710 |
Why?
|
| Health Knowledge, Attitudes, Practice | 15 | 2018 | 894 | 1.690 |
Why?
|
| Thyroid Neoplasms | 9 | 2025 | 255 | 1.690 |
Why?
|
| Texas | 39 | 2025 | 3689 | 1.680 |
Why?
|
| Primary Health Care | 12 | 2019 | 795 | 1.610 |
Why?
|
| Male | 153 | 2025 | 65881 | 1.610 |
Why?
|
| Adrenocortical Carcinoma | 6 | 2023 | 14 | 1.560 |
Why?
|
| Humans | 234 | 2025 | 133931 | 1.550 |
Why?
|
| CD4 Lymphocyte Count | 22 | 2019 | 239 | 1.550 |
Why?
|
| Hospitalization | 9 | 2019 | 1887 | 1.530 |
Why?
|
| HIV Seropositivity | 5 | 2012 | 131 | 1.490 |
Why?
|
| Female | 145 | 2025 | 71658 | 1.460 |
Why?
|
| Health Promotion | 5 | 2017 | 402 | 1.450 |
Why?
|
| Patient Satisfaction | 4 | 2017 | 505 | 1.420 |
Why?
|
| Young Adult | 48 | 2020 | 9887 | 1.390 |
Why?
|
| Ambulatory Care Facilities | 11 | 2022 | 239 | 1.260 |
Why?
|
| Cross-Sectional Studies | 22 | 2024 | 3739 | 1.210 |
Why?
|
| Community Health Centers | 4 | 2014 | 41 | 1.190 |
Why?
|
| Sexual Behavior | 5 | 2020 | 249 | 1.180 |
Why?
|
| Anemia, Sickle Cell | 4 | 2013 | 341 | 1.170 |
Why?
|
| United States | 56 | 2024 | 11683 | 1.160 |
Why?
|
| Risk-Taking | 3 | 2020 | 104 | 1.160 |
Why?
|
| Physicians | 6 | 2022 | 630 | 1.150 |
Why?
|
| Veterans | 15 | 2023 | 1761 | 1.140 |
Why?
|
| Adenocarcinoma, Follicular | 2 | 2025 | 18 | 1.100 |
Why?
|
| Ambulatory Care | 6 | 2015 | 412 | 1.100 |
Why?
|
| Social Support | 5 | 2020 | 380 | 1.090 |
Why?
|
| Child Health Services | 3 | 2013 | 88 | 1.070 |
Why?
|
| Hyperaldosteronism | 7 | 2025 | 22 | 1.070 |
Why?
|
| Healthcare Disparities | 5 | 2024 | 480 | 1.030 |
Why?
|
| Surveys and Questionnaires | 17 | 2025 | 3990 | 1.000 |
Why?
|
| Disease Transmission, Infectious | 2 | 2018 | 88 | 0.980 |
Why?
|
| Medicare | 5 | 2024 | 464 | 0.980 |
Why?
|
| Cohort Studies | 38 | 2023 | 5173 | 0.960 |
Why?
|
| Peer Group | 3 | 2018 | 125 | 0.960 |
Why?
|
| Hepatitis C | 11 | 2010 | 388 | 0.940 |
Why?
|
| Serologic Tests | 3 | 2020 | 131 | 0.910 |
Why?
|
| Adolescent | 47 | 2020 | 20536 | 0.900 |
Why?
|
| Homosexuality, Male | 7 | 2020 | 72 | 0.900 |
Why?
|
| Communication | 5 | 2022 | 541 | 0.890 |
Why?
|
| Drug Prescriptions | 2 | 2024 | 237 | 0.880 |
Why?
|
| Physicians, Primary Care | 2 | 2016 | 97 | 0.870 |
Why?
|
| Aldosterone | 7 | 2025 | 67 | 0.820 |
Why?
|
| Quality of Health Care | 3 | 2013 | 420 | 0.810 |
Why?
|
| Carcinoma | 5 | 2020 | 322 | 0.800 |
Why?
|
| Mutation | 14 | 2025 | 6297 | 0.790 |
Why?
|
| Telemedicine | 4 | 2024 | 499 | 0.790 |
Why?
|
| HIV-1 | 7 | 2022 | 488 | 0.780 |
Why?
|
| Sexual and Gender Minorities | 2 | 2020 | 73 | 0.770 |
Why?
|
| Guidelines as Topic | 2 | 2020 | 201 | 0.760 |
Why?
|
| Adrenocortical Adenoma | 4 | 2025 | 13 | 0.740 |
Why?
|
| Appointments and Schedules | 5 | 2015 | 50 | 0.740 |
Why?
|
| Pre-Exposure Prophylaxis | 3 | 2019 | 51 | 0.740 |
Why?
|
| Pathology, Clinical | 2 | 2020 | 26 | 0.730 |
Why?
|
| Aged | 44 | 2025 | 21730 | 0.700 |
Why?
|
| Health Care Surveys | 7 | 2016 | 293 | 0.700 |
Why?
|
| Text Messaging | 2 | 2019 | 39 | 0.690 |
Why?
|
| Prospective Studies | 17 | 2023 | 6664 | 0.680 |
Why?
|
| Health Services Needs and Demand | 4 | 2019 | 181 | 0.680 |
Why?
|
| Survivors | 2 | 2015 | 360 | 0.680 |
Why?
|
| Practice Guidelines as Topic | 4 | 2018 | 1334 | 0.680 |
Why?
|
| Substance-Related Disorders | 4 | 2021 | 490 | 0.680 |
Why?
|
| Chronic Disease | 4 | 2015 | 1253 | 0.670 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2020 | 40 | 0.660 |
Why?
|
| Insurance, Health | 2 | 2018 | 144 | 0.630 |
Why?
|
| Patient Participation | 2 | 2019 | 234 | 0.620 |
Why?
|
| Soft Tissue Infections | 1 | 2020 | 91 | 0.620 |
Why?
|
| Early Medical Intervention | 2 | 2016 | 30 | 0.600 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2018 | 7 | 0.600 |
Why?
|
| Community-Acquired Infections | 2 | 2020 | 247 | 0.590 |
Why?
|
| Health Services | 2 | 2015 | 73 | 0.590 |
Why?
|
| Adenoma | 4 | 2025 | 142 | 0.580 |
Why?
|
| Attitude to Health | 5 | 2018 | 261 | 0.580 |
Why?
|
| Internal Medicine | 2 | 2023 | 156 | 0.570 |
Why?
|
| Dementia | 1 | 2023 | 486 | 0.570 |
Why?
|
| Unsafe Sex | 1 | 2017 | 24 | 0.570 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2020 | 229 | 0.560 |
Why?
|
| Office Visits | 2 | 2019 | 78 | 0.560 |
Why?
|
| Community Health Workers | 4 | 2015 | 73 | 0.560 |
Why?
|
| Infectious Disease Transmission, Vertical | 4 | 2015 | 253 | 0.550 |
Why?
|
| Drug Monitoring | 2 | 2025 | 181 | 0.540 |
Why?
|
| Interviews as Topic | 6 | 2019 | 418 | 0.540 |
Why?
|
| Patient Outcome Assessment | 2 | 2022 | 95 | 0.540 |
Why?
|
| Patient Selection | 3 | 2017 | 734 | 0.540 |
Why?
|
| Cognition | 1 | 2022 | 815 | 0.540 |
Why?
|
| Mentors | 3 | 2016 | 160 | 0.540 |
Why?
|
| Hospitals, Pediatric | 2 | 2013 | 789 | 0.540 |
Why?
|
| Behavior Therapy | 5 | 2016 | 268 | 0.540 |
Why?
|
| Retrospective Studies | 43 | 2024 | 17481 | 0.540 |
Why?
|
| Counseling | 1 | 2018 | 240 | 0.520 |
Why?
|
| Program Evaluation | 6 | 2019 | 455 | 0.500 |
Why?
|
| Hospitals, Veterans | 3 | 2017 | 357 | 0.490 |
Why?
|
| Health Personnel | 3 | 2025 | 538 | 0.480 |
Why?
|
| Adrenal Gland Neoplasms | 4 | 2025 | 80 | 0.480 |
Why?
|
| Sickness Impact Profile | 1 | 2015 | 39 | 0.480 |
Why?
|
| Guideline Adherence | 2 | 2018 | 395 | 0.480 |
Why?
|
| Socioeconomic Factors | 7 | 2015 | 920 | 0.480 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 875 | 0.480 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2018 | 764 | 0.470 |
Why?
|
| Reverse Transcriptase Inhibitors | 3 | 2011 | 36 | 0.470 |
Why?
|
| Community Health Services | 3 | 2018 | 93 | 0.460 |
Why?
|
| Health Education | 3 | 2015 | 228 | 0.450 |
Why?
|
| Urban Population | 6 | 2023 | 240 | 0.450 |
Why?
|
| Communication Barriers | 1 | 2014 | 41 | 0.450 |
Why?
|
| Veterans Health | 1 | 2016 | 179 | 0.440 |
Why?
|
| Anxiety | 3 | 2021 | 993 | 0.440 |
Why?
|
| Psychometrics | 2 | 2015 | 684 | 0.440 |
Why?
|
| Marketing of Health Services | 1 | 2014 | 25 | 0.440 |
Why?
|
| Protease Inhibitors | 3 | 2015 | 100 | 0.430 |
Why?
|
| Emergency Service, Hospital | 6 | 2018 | 1150 | 0.430 |
Why?
|
| Reminder Systems | 2 | 2011 | 65 | 0.430 |
Why?
|
| Role | 1 | 2013 | 29 | 0.420 |
Why?
|
| Qualitative Research | 7 | 2019 | 636 | 0.410 |
Why?
|
| Inpatients | 3 | 2023 | 535 | 0.410 |
Why?
|
| Social Marketing | 1 | 2013 | 9 | 0.410 |
Why?
|
| Risk Factors | 19 | 2022 | 11086 | 0.400 |
Why?
|
| Kidney Neoplasms | 4 | 2021 | 463 | 0.400 |
Why?
|
| Patient Preference | 1 | 2014 | 135 | 0.390 |
Why?
|
| Depression | 6 | 2022 | 1349 | 0.390 |
Why?
|
| Public Health | 2 | 2016 | 287 | 0.390 |
Why?
|
| Hospitals, Urban | 2 | 2015 | 99 | 0.380 |
Why?
|
| Adenocarcinoma | 10 | 2020 | 1070 | 0.380 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2019 | 168 | 0.380 |
Why?
|
| Internship and Residency | 2 | 2023 | 1250 | 0.380 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2021 | 254 | 0.370 |
Why?
|
| Multivariate Analysis | 9 | 2015 | 1489 | 0.370 |
Why?
|
| Syphilis, Cutaneous | 1 | 2011 | 4 | 0.370 |
Why?
|
| Skin Ulcer | 1 | 2011 | 33 | 0.360 |
Why?
|
| Quality of Life | 4 | 2015 | 2134 | 0.360 |
Why?
|
| Adrenal Cortex | 4 | 2020 | 14 | 0.360 |
Why?
|
| Hospitals, General | 1 | 2011 | 24 | 0.360 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2020 | 962 | 0.360 |
Why?
|
| Delayed Diagnosis | 1 | 2013 | 135 | 0.360 |
Why?
|
| Language | 1 | 2013 | 219 | 0.360 |
Why?
|
| Anus Neoplasms | 4 | 2015 | 43 | 0.360 |
Why?
|
| Sexually Transmitted Diseases, Viral | 1 | 2010 | 4 | 0.360 |
Why?
|
| Parent-Child Relations | 1 | 2013 | 253 | 0.350 |
Why?
|
| Smoking Cessation | 2 | 2024 | 209 | 0.350 |
Why?
|
| Lost to Follow-Up | 3 | 2022 | 33 | 0.350 |
Why?
|
| Poverty | 3 | 2015 | 435 | 0.350 |
Why?
|
| Interpersonal Relations | 1 | 2012 | 229 | 0.350 |
Why?
|
| Attitude of Health Personnel | 4 | 2025 | 711 | 0.350 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2010 | 9 | 0.350 |
Why?
|
| Syphilis | 1 | 2011 | 98 | 0.340 |
Why?
|
| Time Factors | 10 | 2018 | 6588 | 0.340 |
Why?
|
| Motivation | 1 | 2013 | 331 | 0.340 |
Why?
|
| Communications Media | 1 | 2010 | 5 | 0.330 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2011 | 151 | 0.330 |
Why?
|
| Reproducibility of Results | 6 | 2021 | 3054 | 0.330 |
Why?
|
| Pain Measurement | 4 | 2014 | 364 | 0.330 |
Why?
|
| Treatment Outcome | 16 | 2021 | 13011 | 0.330 |
Why?
|
| Pancreatic Neoplasms | 4 | 2010 | 734 | 0.320 |
Why?
|
| Vascular Diseases | 1 | 2011 | 158 | 0.320 |
Why?
|
| Itraconazole | 1 | 2009 | 25 | 0.320 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2009 | 999 | 0.310 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2015 | 484 | 0.310 |
Why?
|
| Self Administration | 2 | 2011 | 45 | 0.310 |
Why?
|
| Genomics | 3 | 2025 | 1676 | 0.310 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2024 | 1201 | 0.310 |
Why?
|
| Sierra Leone | 4 | 2018 | 31 | 0.310 |
Why?
|
| Histoplasmosis | 1 | 2009 | 50 | 0.310 |
Why?
|
| Cytochrome P-450 CYP11B2 | 3 | 2024 | 7 | 0.310 |
Why?
|
| Pilot Projects | 5 | 2024 | 1485 | 0.300 |
Why?
|
| Electronic Health Records | 4 | 2024 | 789 | 0.300 |
Why?
|
| Emergency Medical Services | 1 | 2013 | 415 | 0.300 |
Why?
|
| Regression Analysis | 4 | 2015 | 830 | 0.290 |
Why?
|
| Alcoholism | 2 | 2023 | 249 | 0.280 |
Why?
|
| Liver Neoplasms | 3 | 2009 | 1410 | 0.280 |
Why?
|
| Sleep Wake Disorders | 3 | 2014 | 187 | 0.280 |
Why?
|
| Bile Duct Neoplasms | 1 | 2009 | 121 | 0.270 |
Why?
|
| Cholangiocarcinoma | 1 | 2009 | 121 | 0.270 |
Why?
|
| Self Efficacy | 3 | 2013 | 205 | 0.270 |
Why?
|
| Gene Expression Profiling | 6 | 2015 | 1911 | 0.260 |
Why?
|
| Health Plan Implementation | 2 | 2018 | 44 | 0.260 |
Why?
|
| Esophageal Neoplasms | 6 | 2012 | 393 | 0.260 |
Why?
|
| Patient Education as Topic | 4 | 2019 | 462 | 0.250 |
Why?
|
| Databases, Factual | 1 | 2011 | 1240 | 0.250 |
Why?
|
| Public Health Practice | 2 | 2016 | 20 | 0.250 |
Why?
|
| Prevalence | 8 | 2015 | 2654 | 0.250 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2007 | 225 | 0.240 |
Why?
|
| Self Report | 3 | 2021 | 551 | 0.240 |
Why?
|
| Succinate Dehydrogenase | 1 | 2025 | 9 | 0.240 |
Why?
|
| Prisoners | 4 | 2010 | 38 | 0.240 |
Why?
|
| Paraganglioma | 1 | 2025 | 25 | 0.230 |
Why?
|
| Pheochromocytoma | 1 | 2025 | 39 | 0.230 |
Why?
|
| Logistic Models | 4 | 2015 | 1909 | 0.230 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 9 | 2015 | 1070 | 0.230 |
Why?
|
| Pathology | 2 | 2016 | 43 | 0.230 |
Why?
|
| Adrenalectomy | 1 | 2024 | 40 | 0.230 |
Why?
|
| Internet | 1 | 2007 | 401 | 0.230 |
Why?
|
| Neuropsychological Tests | 3 | 2023 | 983 | 0.230 |
Why?
|
| Biomarkers, Tumor | 7 | 2025 | 1720 | 0.220 |
Why?
|
| Infant | 9 | 2015 | 13161 | 0.220 |
Why?
|
| beta Catenin | 4 | 2023 | 229 | 0.220 |
Why?
|
| Patient Care | 2 | 2016 | 104 | 0.220 |
Why?
|
| Pediatrics | 1 | 2013 | 1217 | 0.210 |
Why?
|
| Medical Oncology | 3 | 2021 | 244 | 0.210 |
Why?
|
| Eosinophilia | 2 | 2014 | 106 | 0.210 |
Why?
|
| Teaching Rounds | 1 | 2023 | 30 | 0.210 |
Why?
|
| Cell Phone | 2 | 2014 | 36 | 0.200 |
Why?
|
| Cation Transport Proteins | 1 | 2023 | 100 | 0.200 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2015 | 874 | 0.200 |
Why?
|
| Child, Preschool | 7 | 2015 | 14800 | 0.200 |
Why?
|
| Creativity | 1 | 2022 | 15 | 0.200 |
Why?
|
| Parents | 3 | 2015 | 1060 | 0.200 |
Why?
|
| Mobile Applications | 1 | 2024 | 109 | 0.190 |
Why?
|
| Adrenal Glands | 3 | 2019 | 54 | 0.190 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 1761 | 0.190 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2012 | 2122 | 0.190 |
Why?
|
| Cell Line, Tumor | 11 | 2020 | 3751 | 0.190 |
Why?
|
| HIV Antibodies | 2 | 2022 | 71 | 0.190 |
Why?
|
| Health Policy | 2 | 2014 | 232 | 0.190 |
Why?
|
| Prognosis | 11 | 2021 | 5074 | 0.180 |
Why?
|
| Executive Function | 1 | 2022 | 125 | 0.180 |
Why?
|
| G Protein-Coupled Inwardly-Rectifying Potassium Channels | 2 | 2023 | 7 | 0.180 |
Why?
|
| Survival Analysis | 5 | 2009 | 1596 | 0.180 |
Why?
|
| Culture | 2 | 2012 | 73 | 0.180 |
Why?
|
| Liver Cirrhosis | 3 | 2007 | 931 | 0.180 |
Why?
|
| Child | 9 | 2016 | 25739 | 0.180 |
Why?
|
| Staphylococcus aureus | 2 | 2020 | 476 | 0.180 |
Why?
|
| Carcinoma, Papillary | 2 | 2016 | 91 | 0.180 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2021 | 20 | 0.180 |
Why?
|
| Pain | 2 | 2014 | 478 | 0.180 |
Why?
|
| Incidence | 10 | 2019 | 3393 | 0.180 |
Why?
|
| Rural Population | 1 | 2023 | 282 | 0.180 |
Why?
|
| Neuroendocrine Tumors | 1 | 2021 | 55 | 0.170 |
Why?
|
| Longitudinal Studies | 4 | 2019 | 1495 | 0.170 |
Why?
|
| Trypanosoma cruzi | 1 | 2024 | 251 | 0.170 |
Why?
|
| Molecular Biology | 1 | 2021 | 80 | 0.170 |
Why?
|
| Housing | 1 | 2020 | 54 | 0.170 |
Why?
|
| Mentoring | 1 | 2022 | 82 | 0.170 |
Why?
|
| Emigrants and Immigrants | 2 | 2013 | 153 | 0.170 |
Why?
|
| Calcium Channels, T-Type | 1 | 2020 | 13 | 0.170 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 1153 | 0.170 |
Why?
|
| Early Diagnosis | 2 | 2014 | 198 | 0.160 |
Why?
|
| Prisons | 2 | 2010 | 13 | 0.160 |
Why?
|
| Chagas Disease | 1 | 2024 | 309 | 0.160 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2003 | 406 | 0.160 |
Why?
|
| Case-Control Studies | 6 | 2018 | 3640 | 0.160 |
Why?
|
| Sequence Analysis, RNA | 2 | 2020 | 429 | 0.160 |
Why?
|
| Social Stigma | 1 | 2020 | 83 | 0.160 |
Why?
|
| Memory Disorders | 1 | 2021 | 235 | 0.160 |
Why?
|
| Aged, 80 and over | 6 | 2017 | 7204 | 0.160 |
Why?
|
| Ribonuclease III | 1 | 2020 | 103 | 0.160 |
Why?
|
| Risk Assessment | 5 | 2015 | 3695 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2017 | 616 | 0.150 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2020 | 147 | 0.150 |
Why?
|
| House Calls | 1 | 2018 | 38 | 0.150 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2012 | 850 | 0.150 |
Why?
|
| Neoplasms | 6 | 2018 | 3027 | 0.150 |
Why?
|
| Drug Therapy, Combination | 3 | 2011 | 1197 | 0.150 |
Why?
|
| Chicago | 1 | 2018 | 20 | 0.150 |
Why?
|
| Sensitivity and Specificity | 4 | 2022 | 2162 | 0.150 |
Why?
|
| Patients | 1 | 2019 | 127 | 0.150 |
Why?
|
| HIV Core Protein p24 | 1 | 2018 | 12 | 0.150 |
Why?
|
| Lung Neoplasms | 3 | 2007 | 1789 | 0.150 |
Why?
|
| Linear Models | 2 | 2013 | 722 | 0.140 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 5505 | 0.140 |
Why?
|
| HIV Serosorting | 1 | 2017 | 1 | 0.140 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 838 | 0.140 |
Why?
|
| Intention | 3 | 2013 | 95 | 0.140 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 387 | 0.140 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 349 | 0.140 |
Why?
|
| Myeloid Cells | 2 | 2021 | 123 | 0.140 |
Why?
|
| Condoms | 1 | 2017 | 50 | 0.140 |
Why?
|
| Gastrins | 1 | 2017 | 34 | 0.140 |
Why?
|
| Health Communication | 1 | 2018 | 31 | 0.140 |
Why?
|
| Minority Health | 1 | 2017 | 13 | 0.140 |
Why?
|
| Factor Analysis, Statistical | 2 | 2015 | 230 | 0.140 |
Why?
|
| Mental Health | 1 | 2021 | 372 | 0.140 |
Why?
|
| Waiting Lists | 1 | 2019 | 244 | 0.140 |
Why?
|
| Tuberculosis | 1 | 2003 | 554 | 0.140 |
Why?
|
| Minority Groups | 2 | 2013 | 255 | 0.140 |
Why?
|
| Sexual Partners | 1 | 2017 | 87 | 0.140 |
Why?
|
| Duodenum | 1 | 2017 | 110 | 0.130 |
Why?
|
| Cluster Analysis | 3 | 2009 | 438 | 0.130 |
Why?
|
| Antigens, Neoplasm | 3 | 2004 | 407 | 0.130 |
Why?
|
| Medically Underserved Area | 1 | 2017 | 94 | 0.130 |
Why?
|
| Perception | 1 | 2018 | 234 | 0.130 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase Catalytic Subunits | 1 | 2016 | 4 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 3475 | 0.130 |
Why?
|
| Program Development | 2 | 2016 | 190 | 0.130 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2017 | 271 | 0.130 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2019 | 216 | 0.130 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2016 | 68 | 0.130 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2016 | 72 | 0.120 |
Why?
|
| Risk | 2 | 2009 | 831 | 0.120 |
Why?
|
| Pyloric Antrum | 1 | 2015 | 63 | 0.120 |
Why?
|
| Sex Factors | 3 | 2010 | 1384 | 0.120 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 148 | 0.120 |
Why?
|
| Antiviral Agents | 3 | 2010 | 825 | 0.120 |
Why?
|
| Self-Assessment | 1 | 2015 | 65 | 0.120 |
Why?
|
| Neuroglia | 1 | 2017 | 217 | 0.120 |
Why?
|
| Proportional Hazards Models | 4 | 2021 | 1483 | 0.120 |
Why?
|
| Liver Diseases | 3 | 2007 | 388 | 0.120 |
Why?
|
| Survival Rate | 3 | 2010 | 2207 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 2 | 2018 | 1833 | 0.110 |
Why?
|
| Cities | 1 | 2014 | 51 | 0.110 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 697 | 0.110 |
Why?
|
| Disease Progression | 4 | 2019 | 2239 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2005 | 138 | 0.110 |
Why?
|
| Homeostasis | 2 | 2015 | 749 | 0.110 |
Why?
|
| Splints | 1 | 2013 | 10 | 0.110 |
Why?
|
| Cell Lineage | 2 | 2015 | 369 | 0.110 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2014 | 77 | 0.110 |
Why?
|
| Hepacivirus | 3 | 2010 | 273 | 0.110 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2013 | 22 | 0.110 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2013 | 12 | 0.110 |
Why?
|
| Visual Analog Scale | 1 | 2013 | 7 | 0.110 |
Why?
|
| Birt-Hogg-Dube Syndrome | 1 | 2013 | 6 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 1315 | 0.110 |
Why?
|
| Professional-Patient Relations | 1 | 2014 | 89 | 0.110 |
Why?
|
| Hepatitis C, Chronic | 2 | 2010 | 373 | 0.110 |
Why?
|
| Receptors, Notch | 1 | 2015 | 214 | 0.100 |
Why?
|
| MicroRNAs | 2 | 2013 | 951 | 0.100 |
Why?
|
| Patient Advocacy | 1 | 2013 | 62 | 0.100 |
Why?
|
| Research Support as Topic | 1 | 2013 | 66 | 0.100 |
Why?
|
| Neuralgia | 1 | 2013 | 57 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 2520 | 0.100 |
Why?
|
| Failure to Thrive | 1 | 2013 | 92 | 0.100 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2014 | 138 | 0.100 |
Why?
|
| Violence | 1 | 2013 | 124 | 0.100 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2015 | 315 | 0.100 |
Why?
|
| Centralized Hospital Services | 1 | 2012 | 5 | 0.100 |
Why?
|
| Emtricitabine | 1 | 2012 | 3 | 0.100 |
Why?
|
| Homosexuality | 2 | 2010 | 18 | 0.100 |
Why?
|
| Stem Cells | 2 | 2015 | 753 | 0.100 |
Why?
|
| Tenofovir | 1 | 2012 | 23 | 0.100 |
Why?
|
| Organophosphonates | 1 | 2012 | 21 | 0.100 |
Why?
|
| Leiomyomatosis | 1 | 2012 | 8 | 0.100 |
Why?
|
| GATA6 Transcription Factor | 1 | 2012 | 12 | 0.100 |
Why?
|
| Benzoxazines | 1 | 2012 | 23 | 0.100 |
Why?
|
| Alkynes | 1 | 2012 | 26 | 0.100 |
Why?
|
| Gene Amplification | 3 | 2012 | 247 | 0.100 |
Why?
|
| Adaptation, Psychological | 1 | 2015 | 447 | 0.100 |
Why?
|
| Pneumonia, Pneumococcal | 2 | 2009 | 87 | 0.100 |
Why?
|
| Neoplasm Metastasis | 3 | 2025 | 746 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2019 | 1143 | 0.090 |
Why?
|
| Deoxycytidine | 1 | 2012 | 84 | 0.090 |
Why?
|
| Cyclopropanes | 1 | 2012 | 70 | 0.090 |
Why?
|
| Spouses | 1 | 2012 | 71 | 0.090 |
Why?
|
| Health Surveys | 1 | 2013 | 258 | 0.090 |
Why?
|
| Child, Exceptional | 1 | 2011 | 3 | 0.090 |
Why?
|
| Motivational Interviewing | 1 | 2012 | 52 | 0.090 |
Why?
|
| Stereotyping | 1 | 2011 | 20 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2015 | 404 | 0.090 |
Why?
|
| Adenine | 1 | 2012 | 122 | 0.090 |
Why?
|
| ROC Curve | 1 | 2013 | 615 | 0.090 |
Why?
|
| Poisson Distribution | 1 | 2011 | 52 | 0.090 |
Why?
|
| Family Practice | 1 | 2011 | 93 | 0.090 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2012 | 76 | 0.090 |
Why?
|
| Rural Health | 1 | 2011 | 51 | 0.090 |
Why?
|
| Video Recording | 1 | 2013 | 204 | 0.090 |
Why?
|
| Community-Institutional Relations | 1 | 2011 | 35 | 0.090 |
Why?
|
| Niacin | 1 | 2011 | 59 | 0.090 |
Why?
|
| Fenofibrate | 1 | 2011 | 61 | 0.090 |
Why?
|
| Sulfamethizole | 1 | 2010 | 1 | 0.090 |
Why?
|
| Trimethoprim | 1 | 2010 | 4 | 0.090 |
Why?
|
| Dapsone | 1 | 2010 | 6 | 0.090 |
Why?
|
| Genes, pol | 1 | 2010 | 10 | 0.090 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2010 | 17 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 352 | 0.090 |
Why?
|
| Adiponectin | 1 | 2011 | 127 | 0.090 |
Why?
|
| Costs and Cost Analysis | 1 | 2011 | 165 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 567 | 0.090 |
Why?
|
| Safe Sex | 1 | 2010 | 16 | 0.090 |
Why?
|
| Anemia, Hemolytic | 1 | 2010 | 32 | 0.090 |
Why?
|
| Drug Resistance, Viral | 1 | 2010 | 50 | 0.090 |
Why?
|
| Focus Groups | 1 | 2011 | 214 | 0.080 |
Why?
|
| Disability Evaluation | 1 | 2011 | 194 | 0.080 |
Why?
|
| Life Expectancy | 1 | 2010 | 59 | 0.080 |
Why?
|
| Health Facilities | 1 | 2010 | 67 | 0.080 |
Why?
|
| Affect | 1 | 2011 | 173 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 148 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2010 | 66 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2013 | 505 | 0.080 |
Why?
|
| Signal Transduction | 4 | 2023 | 4900 | 0.080 |
Why?
|
| Viremia | 1 | 2010 | 136 | 0.080 |
Why?
|
| Gene Expression | 2 | 2016 | 1614 | 0.080 |
Why?
|
| Needs Assessment | 1 | 2011 | 184 | 0.080 |
Why?
|
| Radiation Tolerance | 1 | 2010 | 67 | 0.080 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 86 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2010 | 283 | 0.080 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2009 | 13 | 0.080 |
Why?
|
| Disease Management | 1 | 2013 | 560 | 0.080 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2010 | 176 | 0.080 |
Why?
|
| Hepatitis B | 2 | 2008 | 172 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 162 | 0.080 |
Why?
|
| Age Factors | 3 | 2011 | 2977 | 0.080 |
Why?
|
| Cyclin E | 1 | 2009 | 33 | 0.080 |
Why?
|
| Ovarian Neoplasms | 1 | 2013 | 464 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 1409 | 0.080 |
Why?
|
| Pregnancy | 5 | 2015 | 7523 | 0.080 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2009 | 29 | 0.080 |
Why?
|
| RNA Interference | 4 | 2016 | 544 | 0.080 |
Why?
|
| Haemophilus Infections | 1 | 2009 | 95 | 0.080 |
Why?
|
| Haemophilus influenzae | 1 | 2009 | 134 | 0.080 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2009 | 50 | 0.070 |
Why?
|
| Piperazines | 1 | 2010 | 257 | 0.070 |
Why?
|
| Physician's Role | 1 | 2010 | 171 | 0.070 |
Why?
|
| Blotting, Western | 6 | 2010 | 1134 | 0.070 |
Why?
|
| Research | 1 | 2010 | 272 | 0.070 |
Why?
|
| Health Resources | 2 | 2014 | 125 | 0.070 |
Why?
|
| Proteomics | 2 | 2021 | 592 | 0.070 |
Why?
|
| Informed Consent | 1 | 2011 | 345 | 0.070 |
Why?
|
| Pneumonia, Bacterial | 1 | 2009 | 81 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2009 | 261 | 0.070 |
Why?
|
| Dyslipidemias | 1 | 2011 | 244 | 0.070 |
Why?
|
| Animals | 11 | 2023 | 36398 | 0.070 |
Why?
|
| Cause of Death | 2 | 2014 | 502 | 0.070 |
Why?
|
| Malawi | 3 | 2015 | 423 | 0.070 |
Why?
|
| Transcription, Genetic | 3 | 2009 | 1757 | 0.070 |
Why?
|
| Pediatric Obesity | 1 | 2013 | 405 | 0.070 |
Why?
|
| Wnt Proteins | 1 | 2009 | 223 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2010 | 269 | 0.070 |
Why?
|
| SEER Program | 1 | 2009 | 224 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2022 | 816 | 0.070 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2007 | 45 | 0.070 |
Why?
|
| Hyperglycemia | 1 | 2009 | 242 | 0.070 |
Why?
|
| Cryoglobulinemia | 1 | 2007 | 11 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2011 | 3072 | 0.070 |
Why?
|
| Social Class | 1 | 2008 | 205 | 0.070 |
Why?
|
| Odds Ratio | 4 | 2013 | 1337 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 1162 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 548 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2010 | 417 | 0.070 |
Why?
|
| Neurocysticercosis | 1 | 2007 | 27 | 0.070 |
Why?
|
| International Classification of Diseases | 1 | 2007 | 99 | 0.070 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2006 | 41 | 0.070 |
Why?
|
| Gene Expression Regulation | 3 | 2017 | 2656 | 0.070 |
Why?
|
| Metabolic Syndrome | 1 | 2010 | 366 | 0.070 |
Why?
|
| Streptococcus pneumoniae | 1 | 2009 | 383 | 0.060 |
Why?
|
| Infant, Newborn | 3 | 2022 | 8592 | 0.060 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2007 | 172 | 0.060 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2007 | 225 | 0.060 |
Why?
|
| Pancreatitis | 2 | 2004 | 144 | 0.060 |
Why?
|
| Prejudice | 1 | 2006 | 39 | 0.060 |
Why?
|
| Chromosome Fragile Sites | 1 | 2006 | 5 | 0.060 |
Why?
|
| Papanicolaou Test | 1 | 2006 | 36 | 0.060 |
Why?
|
| Receptors, Growth Factor | 1 | 2006 | 37 | 0.060 |
Why?
|
| Vaginal Smears | 1 | 2006 | 52 | 0.060 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2007 | 705 | 0.060 |
Why?
|
| Acute Coronary Syndrome | 1 | 2009 | 234 | 0.060 |
Why?
|
| Interferon Regulatory Factor-2 | 1 | 2005 | 5 | 0.060 |
Why?
|
| Ganglioneuroma | 1 | 2005 | 18 | 0.060 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2005 | 16 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2006 | 100 | 0.060 |
Why?
|
| Genome | 1 | 2009 | 526 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 611 | 0.060 |
Why?
|
| Asthma | 1 | 2013 | 811 | 0.060 |
Why?
|
| Urban Health Services | 1 | 2005 | 22 | 0.060 |
Why?
|
| Tissue Array Analysis | 1 | 2005 | 143 | 0.060 |
Why?
|
| Pandemics | 2 | 2023 | 1196 | 0.060 |
Why?
|
| Turner Syndrome | 1 | 2005 | 46 | 0.060 |
Why?
|
| X-linked Nuclear Protein | 1 | 2025 | 19 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2013 | 866 | 0.060 |
Why?
|
| DNA Repair Enzymes | 1 | 2025 | 48 | 0.060 |
Why?
|
| DNA Modification Methylases | 1 | 2025 | 52 | 0.060 |
Why?
|
| Cell Survival | 2 | 2021 | 891 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2012 | 644 | 0.060 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2004 | 24 | 0.060 |
Why?
|
| Calreticulin | 1 | 2004 | 21 | 0.060 |
Why?
|
| Medical Records | 1 | 2005 | 194 | 0.060 |
Why?
|
| Gene Silencing | 2 | 2019 | 248 | 0.060 |
Why?
|
| San Francisco | 1 | 2004 | 18 | 0.060 |
Why?
|
| Uncompensated Care | 1 | 2004 | 11 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2005 | 363 | 0.060 |
Why?
|
| Smokers | 1 | 2024 | 45 | 0.050 |
Why?
|
| Telomerase | 1 | 2025 | 180 | 0.050 |
Why?
|
| Osteomyelitis | 1 | 2007 | 211 | 0.050 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2007 | 154 | 0.050 |
Why?
|
| Autoantibodies | 2 | 2004 | 466 | 0.050 |
Why?
|
| RNA, Messenger | 4 | 2020 | 2903 | 0.050 |
Why?
|
| Liver Failure, Acute | 1 | 2005 | 96 | 0.050 |
Why?
|
| Mutation, Missense | 2 | 2020 | 931 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2016 | 1607 | 0.050 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2005 | 198 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2006 | 288 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2006 | 905 | 0.050 |
Why?
|
| Zinc | 1 | 2023 | 141 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2007 | 792 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 756 | 0.050 |
Why?
|
| Telephone | 1 | 2023 | 127 | 0.050 |
Why?
|
| Microtubule Proteins | 1 | 2002 | 29 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2003 | 80 | 0.050 |
Why?
|
| Algorithms | 3 | 2024 | 1735 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2025 | 406 | 0.050 |
Why?
|
| Colon | 1 | 2005 | 379 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2025 | 510 | 0.050 |
Why?
|
| DNA, Bacterial | 1 | 2003 | 498 | 0.050 |
Why?
|
| Alternative Splicing | 1 | 2004 | 375 | 0.050 |
Why?
|
| Cystic Fibrosis | 1 | 2004 | 264 | 0.050 |
Why?
|
| RNA, Viral | 3 | 2010 | 562 | 0.050 |
Why?
|
| Staphylococcal Infections | 1 | 2007 | 573 | 0.050 |
Why?
|
| Comorbidity | 2 | 2021 | 1614 | 0.050 |
Why?
|
| Homeodomain Proteins | 1 | 2005 | 584 | 0.050 |
Why?
|
| Mice | 8 | 2016 | 18911 | 0.050 |
Why?
|
| Cellular Senescence | 1 | 2023 | 201 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2006 | 398 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2005 | 571 | 0.050 |
Why?
|
| Point Mutation | 1 | 2002 | 360 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2003 | 336 | 0.040 |
Why?
|
| Feedback | 1 | 2022 | 166 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2006 | 1087 | 0.040 |
Why?
|
| Mice, Nude | 3 | 2010 | 777 | 0.040 |
Why?
|
| Lebanon | 1 | 2020 | 7 | 0.040 |
Why?
|
| Mental Recall | 1 | 2021 | 142 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2005 | 2764 | 0.040 |
Why?
|
| Data Collection | 2 | 2013 | 397 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2020 | 46 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 431 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 137 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2013 | 714 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2021 | 941 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 1850 | 0.040 |
Why?
|
| Patient Navigation | 1 | 2020 | 27 | 0.040 |
Why?
|
| Observer Variation | 2 | 2016 | 312 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2016 | 224 | 0.040 |
Why?
|
| Machine Learning | 1 | 2024 | 331 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2008 | 881 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2002 | 456 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 2020 | 104 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2004 | 718 | 0.040 |
Why?
|
| Pharmacists | 1 | 2020 | 99 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2005 | 815 | 0.040 |
Why?
|
| Lentivirus | 1 | 2020 | 86 | 0.040 |
Why?
|
| Chromatin | 1 | 2023 | 609 | 0.040 |
Why?
|
| RNA, Neoplasm | 1 | 2020 | 144 | 0.040 |
Why?
|
| Proteome | 1 | 2001 | 281 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 33 | 0.040 |
Why?
|
| Doxycycline | 1 | 2020 | 121 | 0.040 |
Why?
|
| Smoking | 1 | 2005 | 1139 | 0.040 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 3 | 2004 | 47 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 1326 | 0.040 |
Why?
|
| Angiotensin II | 1 | 2020 | 168 | 0.040 |
Why?
|
| Software | 1 | 2024 | 737 | 0.040 |
Why?
|
| Directly Observed Therapy | 1 | 2018 | 25 | 0.040 |
Why?
|
| Data Mining | 1 | 2019 | 58 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2009 | 300 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 3 | 2006 | 1102 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 690 | 0.040 |
Why?
|
| Registries | 2 | 2019 | 1563 | 0.040 |
Why?
|
| Genes, Neoplasm | 2 | 2012 | 90 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2007 | 2196 | 0.040 |
Why?
|
| Tablets | 1 | 2018 | 36 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2019 | 317 | 0.040 |
Why?
|
| Calcium Signaling | 1 | 2020 | 255 | 0.040 |
Why?
|
| Health Services Research | 1 | 2019 | 191 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 307 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 773 | 0.040 |
Why?
|
| Receptor, Cholecystokinin B | 1 | 2017 | 2 | 0.040 |
Why?
|
| Gastrinoma | 1 | 2017 | 3 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2018 | 171 | 0.040 |
Why?
|
| Duodenal Neoplasms | 1 | 2017 | 23 | 0.030 |
Why?
|
| CpG Islands | 1 | 2019 | 347 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2021 | 545 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2017 | 65 | 0.030 |
Why?
|
| Receptors, Somatostatin | 1 | 2017 | 56 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2019 | 366 | 0.030 |
Why?
|
| Consensus | 1 | 2021 | 739 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2017 | 132 | 0.030 |
Why?
|
| Hyperplasia | 1 | 2017 | 203 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2017 | 115 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 678 | 0.030 |
Why?
|
| Uganda | 1 | 2017 | 89 | 0.030 |
Why?
|
| Research Design | 2 | 2013 | 754 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 132 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2017 | 170 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2017 | 183 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2016 | 2539 | 0.030 |
Why?
|
| Proteolysis | 1 | 2017 | 194 | 0.030 |
Why?
|
| Phenotype | 2 | 2019 | 4547 | 0.030 |
Why?
|
| Cushing Syndrome | 1 | 2016 | 22 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 667 | 0.030 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2016 | 45 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2016 | 94 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 104 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 1439 | 0.030 |
Why?
|
| Databases, Nucleic Acid | 1 | 2016 | 74 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2020 | 970 | 0.030 |
Why?
|
| Zona Glomerulosa | 1 | 2015 | 4 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2021 | 749 | 0.030 |
Why?
|
| Histological Techniques | 1 | 2015 | 22 | 0.030 |
Why?
|
| Probability | 2 | 2007 | 335 | 0.030 |
Why?
|
| Aging | 1 | 2023 | 1302 | 0.030 |
Why?
|
| Body Weights and Measures | 1 | 2015 | 45 | 0.030 |
Why?
|
| GTP Phosphohydrolases | 1 | 2016 | 159 | 0.030 |
Why?
|
| Thyroidectomy | 1 | 2016 | 114 | 0.030 |
Why?
|
| Thyroid Gland | 1 | 2016 | 115 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2016 | 242 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2018 | 702 | 0.030 |
Why?
|
| Recurrence | 1 | 2019 | 1471 | 0.030 |
Why?
|
| District of Columbia | 1 | 2014 | 17 | 0.030 |
Why?
|
| Financial Support | 1 | 2014 | 8 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2015 | 160 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 205 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2005 | 2704 | 0.030 |
Why?
|
| Health Behavior | 1 | 2018 | 402 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 2295 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2015 | 484 | 0.030 |
Why?
|
| Walk Test | 1 | 2014 | 28 | 0.030 |
Why?
|
| Proton Pump Inhibitors | 1 | 2017 | 285 | 0.030 |
Why?
|
| Barrett Esophagus | 2 | 2012 | 355 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2014 | 91 | 0.030 |
Why?
|
| Kidney | 1 | 2021 | 1410 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 371 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2015 | 166 | 0.030 |
Why?
|
| Training Support | 1 | 2013 | 19 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 695 | 0.030 |
Why?
|
| Exanthema | 1 | 2014 | 71 | 0.030 |
Why?
|
| Premedication | 1 | 2013 | 42 | 0.030 |
Why?
|
| Co-Repressor Proteins | 1 | 2013 | 39 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 1996 | 383 | 0.030 |
Why?
|
| Standard of Care | 1 | 2014 | 136 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 1046 | 0.030 |
Why?
|
| Exercise Test | 1 | 2014 | 267 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 542 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2015 | 836 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 896 | 0.030 |
Why?
|
| Apoptosis | 2 | 2012 | 1931 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 456 | 0.020 |
Why?
|
| Cell Communication | 1 | 2013 | 186 | 0.020 |
Why?
|
| Mortality | 1 | 2014 | 262 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2012 | 77 | 0.020 |
Why?
|
| Community Networks | 1 | 2012 | 33 | 0.020 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2012 | 25 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2012 | 61 | 0.020 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2012 | 36 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2012 | 64 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2013 | 188 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 1386 | 0.020 |
Why?
|
| Colonic Neoplasms | 2 | 2005 | 271 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 129 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2017 | 3167 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 724 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2012 | 363 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 333 | 0.020 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2010 | 21 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2010 | 50 | 0.020 |
Why?
|
| Sleep | 1 | 2013 | 368 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 2527 | 0.020 |
Why?
|
| Faculty, Medical | 1 | 2013 | 281 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2010 | 64 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2012 | 577 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2006 | 3970 | 0.020 |
Why?
|
| Benzamides | 1 | 2010 | 125 | 0.020 |
Why?
|
| Pedigree | 1 | 2013 | 1694 | 0.020 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2010 | 97 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2011 | 187 | 0.020 |
Why?
|
| DNA | 1 | 2015 | 1675 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2012 | 359 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2010 | 148 | 0.020 |
Why?
|
| Health Planning | 1 | 2009 | 16 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2017 | 3980 | 0.020 |
Why?
|
| Alabama | 1 | 2009 | 47 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2009 | 52 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2004 | 2785 | 0.020 |
Why?
|
| Transcriptome | 1 | 2015 | 1127 | 0.020 |
Why?
|
| Triglycerides | 1 | 2011 | 613 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2009 | 207 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 971 | 0.020 |
Why?
|
| Life Style | 1 | 2011 | 454 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 4821 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2015 | 2026 | 0.020 |
Why?
|
| Anticholesteremic Agents | 1 | 2010 | 245 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 1667 | 0.020 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2007 | 59 | 0.020 |
Why?
|
| Growth Inhibitors | 1 | 2006 | 40 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 1006 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2007 | 183 | 0.020 |
Why?
|
| Boronic Acids | 1 | 2006 | 48 | 0.020 |
Why?
|
| Methicillin Resistance | 1 | 2007 | 118 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2006 | 83 | 0.020 |
Why?
|
| Embryonic Stem Cells | 1 | 2007 | 177 | 0.020 |
Why?
|
| Mitosis | 1 | 2006 | 194 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2006 | 30 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2006 | 30 | 0.020 |
Why?
|
| Rifampin | 1 | 2007 | 134 | 0.020 |
Why?
|
| 5' Untranslated Regions | 1 | 2006 | 61 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 1139 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 2006 | 73 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2006 | 260 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2006 | 204 | 0.020 |
Why?
|
| CDX2 Transcription Factor | 1 | 2005 | 10 | 0.010 |
Why?
|
| Transcription Initiation Site | 1 | 2005 | 34 | 0.010 |
Why?
|
| Tumor Escape | 1 | 2005 | 65 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2006 | 240 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2007 | 570 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 2005 | 65 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2009 | 542 | 0.010 |
Why?
|
| Feedback, Physiological | 1 | 2005 | 72 | 0.010 |
Why?
|
| Papillomaviridae | 1 | 2006 | 189 | 0.010 |
Why?
|
| Microdissection | 1 | 2004 | 14 | 0.010 |
Why?
|
| Response Elements | 1 | 2005 | 106 | 0.010 |
Why?
|
| Exercise | 1 | 2011 | 877 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 2005 | 107 | 0.010 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2004 | 10 | 0.010 |
Why?
|
| Genome, Human | 1 | 2012 | 1350 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2007 | 627 | 0.010 |
Why?
|
| Transfection | 1 | 2006 | 1089 | 0.010 |
Why?
|
| Vancomycin | 1 | 2007 | 236 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2006 | 453 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2007 | 730 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 1814 | 0.010 |
Why?
|
| Genomic Instability | 1 | 2006 | 244 | 0.010 |
Why?
|
| Glycosylation | 1 | 2004 | 127 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 260 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 399 | 0.010 |
Why?
|
| Genotype | 1 | 2010 | 2807 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 1315 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 444 | 0.010 |
Why?
|
| Genes | 1 | 2004 | 450 | 0.010 |
Why?
|
| Pancreas | 1 | 2004 | 233 | 0.010 |
Why?
|
| Metaplasia | 1 | 2004 | 219 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 742 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2004 | 302 | 0.010 |
Why?
|
| Hypoxia | 1 | 2005 | 262 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2004 | 429 | 0.010 |
Why?
|
| Drug Therapy | 1 | 2003 | 93 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2005 | 538 | 0.010 |
Why?
|
| Stathmin | 1 | 2002 | 2 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2004 | 371 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2002 | 123 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2005 | 717 | 0.010 |
Why?
|
| Gastrointestinal Tract | 1 | 2005 | 243 | 0.010 |
Why?
|
| Tubulin | 1 | 2002 | 76 | 0.010 |
Why?
|
| Iron | 1 | 2005 | 303 | 0.010 |
Why?
|
| Liver | 1 | 2010 | 1875 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 2837 | 0.010 |
Why?
|
| Microtubules | 1 | 2002 | 131 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2002 | 433 | 0.010 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2001 | 70 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 3849 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2001 | 312 | 0.010 |
Why?
|
| Base Sequence | 1 | 2006 | 3171 | 0.010 |
Why?
|
| RNA | 1 | 2005 | 601 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 774 | 0.010 |
Why?
|
| Biomarkers | 1 | 2010 | 3423 | 0.010 |
Why?
|
| Models, Biological | 1 | 2005 | 1533 | 0.010 |
Why?
|
| Proteins | 1 | 2005 | 1087 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2002 | 1702 | 0.010 |
Why?
|
| Lung | 1 | 2005 | 1557 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1996 | 305 | 0.010 |
Why?
|